Since the identification of these genes in 1994 and 1995 [5,6], evidence has grown to support the development of clear recommendations regarding the optimal management of BRCA1/2 PV carriers, through which cancer rates and all-cause mortality can be improved [7,8,9]. This evidence concerns the gene BRCA1 and cancer.